Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006

BACKGROUND: We analyzed cases of malignant hyperthermia (MH) reported to the North American MH Registry for clinical characteristics, treatment, and complications. METHODS: Our inclusion criteria were as follows: AMRA (adverse metabolic/musculoskeletal reaction to anesthesia) reports between January 1, 1987 and December 31, 2006; “very likely” or “almost certain” MH as ranked by the clinical grading scale; United States or Canadian location; and more than one anesthetic drug given. An exclusion criterion was pathology other than MH; for complication analysis, patients with unknown status or minor complications attributable to dantrolene were excluded. Wilcoxon rank sum and Pearson exact &khgr;2 tests were applied. A multivariable model of the risk of complications from MH was created through stepwise selection with fit judged by the Hosmer-Lemeshow statistic. RESULTS: Young males (74.8%) dominated in 286 episodes. A total of 6.5% had an MH family history; 77 of 152 patients with MH reported ≥2 prior unremarkable general anesthetics. In 10 cases, skin liquid crystal temperature did not trend. Frequent initial MH signs were hypercarbia, sinus tachycardia, or masseter spasm. In 63.5%, temperature abnormality (median maximum, 39.1°C) was the first to third sign. Whereas 78.6% presented with both muscular abnormalities and respiratory acidosis, only 26.0% had metabolic acidosis. The median total dantrolene dose was 5.9 mg/kg (first quartile, 3.0 mg/kg; third quartile, 10.0 mg/kg), although 22 patients received no dantrolene and survived. A total of 53.9% received bicarbonate therapy. Complications not including recrudescence, cardiac arrest, or death occurred in 63 of 181 patients (34.8%) with MH. Twenty-one experienced hematologic and/or neurologic complications with a temperature <41.6°C (human critical thermal maximum). The likelihood of any complication increased 2.9 times per 2°C increase in maximum temperature and 1.6 times per 30-minute delay in dantrolene use. CONCLUSION: Elevated temperature may be an early MH sign. Although increased temperature occurs frequently, metabolic acidosis occurs one-third as often. Accurate temperature monitoring during general anesthetics and early dantrolene administration may decrease the 35% MH morbidity rate.

[1]  R. Kaplan,et al.  Postoperative Malignant Hyperthermia: An Analysis of Cases from the North American Malignant Hyperthermia Registry , 2008, Anesthesiology.

[2]  D. Sessler,et al.  Temperature Monitoring and Perioperative Thermoregulation , 2008, Anesthesiology.

[3]  E. Lehman,et al.  Cardiac Arrests and Deaths Associated with Malignant Hyperthermia in North America from 1987 to 2006: A Report from The North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States , 2008, Anesthesiology.

[4]  K. Domino,et al.  Analysis of the Clinical Variables Associated with Recrudescence after Malignant Hyperthermia Reactions , 2007, Anesthesiology.

[5]  Beverley McNeil,et al.  Malignant Hyperthermia , 2005, Springer US.

[6]  W W Mapleson,et al.  Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. , 2003, British journal of anaesthesia.

[7]  A. Kunselman,et al.  The Sensitivity and Specificity of the Caffeine‐Halothane Contracture Test: A Report from the North American Malignant Hyperthermia Registry , 1998 .

[8]  F. Lehmann-Horn,et al.  In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low‐risk subjects , 1997, Acta anaesthesiologica Scandinavica.

[9]  D. Chartrand,et al.  Clinical reassessment of malignant hyperthermia in Abitibi-Témiscamingue , 1997, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[10]  P. Iaizzo,et al.  Thermal Response in Acute Porcine Malignant Hyperthermia , 1996, Anesthesia and analgesia.

[11]  W W Mapleson,et al.  Effect of age on MAC in humans: a meta-analysis. , 1996, British journal of anaesthesia.

[12]  A. Localio,et al.  A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.

[13]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[14]  Y. Hochberg A sharper Bonferroni procedure for multiple tests of significance , 1988 .

[15]  W. Mauritz,et al.  [Malignant hyperthermia in Austria. I. Epidemiology and clinical aspects]. , 1986, Der Anaesthesist.

[16]  H. Ørding Incidence of Malignant Hyperthermia in Denmark , 1985 .

[17]  M. L. Horne,et al.  Dantrolene in Human Malignant Hyperthermia A Multicenter Study , 1982 .

[18]  W. Forrest A collaborative clinical trial on trial. , 1982, Anesthesiology.

[19]  M. Marchildon Malignant hyperthermia. Current concepts. , 1982, Archives of surgery.

[20]  P. Halsall,et al.  Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized. , 1979, British journal of anaesthesia.

[21]  R. F. Goldman,et al.  Induced hyperthermia in sedated humans and the concept of critical thermal maximum. , 1978, The American journal of physiology.

[22]  B. Britt,et al.  Malignant hyperthermia: A statistical review , 1970, Canadian Anaesthetists' Society journal.

[23]  E. Eger,et al.  The Relationship between Age and Halothane Requirement in Man , 1969, Anesthesiology.

[24]  Ronald D. Miller Miller's Anesthesia , 2005 .

[25]  J. Knochel,et al.  Medical progress: Heat stroke , 2002 .

[26]  H. Ording Incidence of malignant hyperthermia in Denmark. , 1985, Anesthesia and analgesia.

[27]  P. Gottschalk,et al.  Heat Stroke , 1912 .